ABS-201 - (HEADLINE)

May 7, 2026: Absci Corporation (NASDAQ: ABSI) reported Q1 2026 results and provided pipeline updates highlighted by progress in its Phase 1/2a HEADLINE trial of ABS-201, a long-acting anti–prolactin receptor (PRLR) antibody.

ABS-201 (androgenetic alopecia): The company completed dosing of all four planned healthy-volunteer single ascending dose (SAD) cohorts; ABS-201 has been well tolerated to date with “favorable emerging” safety data. Preliminary PK modeling from the trial supports a targeted dosing interval of two or three injections over a six-month period. Absci also initiated dosing of the first multiple ascending dose (MAD) cohort in AGA participants. Upcoming catalysts: preliminary safety/tolerability/PK data in Q2 2026; interim proof-of-concept data in 2H 2026; full proof-of-concept data in early 2027.

ABS-201 (endometriosis): Absci formed an endometriosis clinical advisory board and expects to initiate a Phase 2 trial in Q4 2026, with potential proof-of-concept data in 2H 2027.

ABS-202 (I&I): Added a second anti-PRLR antibody program, ABS-202, in preclinical development for an undisclosed inflammation/immunology indication.

The release also lists multiple accepted 2026 scientific presentations/abstracts related to prolactin/PRLR biology, ABS-201, and the company’s Origin-1 antibody design platform.